Levosimendan Fresenius Kabi

Levosimendan, the active ingredient in Levosimendan Fresenius Kabi, is a calcium sensitizer presented as an intravenous solution for intravenous use. It is employed in the management of acute decompensated heart failure and severe chronic heart failure, offering inotropic support for patients requiring hospital‑based therapy.

GNH USA supplies Levosimendan Fresenius Kabi as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and clinics worldwide, with the product sourced from the European Union market. The company adheres to strict quality standards and provides full regulatory documentation to facilitate import and distribution.

Levosimendan is used in the management of heart failure syndromes where enhanced cardiac contractility is required.

- Acute decompensated heart failure: improves cardiac output and reduces symptoms in hospitalized patients. - Severe chronic heart failure: provides inotropic support as an adjunct to standard therapy in patients with low output. - Cardiogenic shock (off‑label): may be employed to stabilize hemodynamics when conventional agents are insufficient.

Levosimendan may be associated with several adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Headache: mild to moderate intensity. - Nausea: occasional gastrointestinal upset. - Hypotension: transient drop in blood pressure. - Tachycardia: increased heart rate. - Dizziness: light‑headed sensation.

Serious or Rare Side Effects: - Ventricular arrhythmias: potentially life‑threatening rhythm disturbances. - Myocardial ischemia: reduced coronary blood flow. - Severe hypotension: refractory low blood pressure requiring intervention. - Allergic reactions: rash, pruritus, or anaphylaxis.

When using Levosimendan, clinicians should observe specific precautions to minimize risk.

- Cardiovascular monitoring: continuous ECG and blood pressure monitoring during infusion. - Electrolyte balance: correct hypokalemia and hypomagnesemia before administration. - Concomitant vasodilators: use cautiously with other vasodilators to avoid excessive hypotension. - Renal impairment: adjust infusion rate and monitor renal function closely. - Hepatic dysfunction: consider reduced clearance in patients with severe liver disease. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Levosimendan can interact with several medicines, influencing its efficacy or safety.

Major Interactions (Avoid): - Nitrates: additive vasodilatory effect may cause severe hypotension. - Beta‑blockers: may blunt the inotropic response.

Moderate Interactions (Monitor Closely): - Calcium channel blockers: can enhance vasodilatory response. - Diuretics: may exacerbate electrolyte disturbances. - ACE inhibitors/ARBs: combined effect on blood pressure requires monitoring. - Anticoagulants: potential for increased bleeding risk due to vasodilation‑related platelet effects.